These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 4051846)

  • 1. Free plasma fluorescein.
    Kisly A; Vine AK
    Arch Ophthalmol; 1985 Oct; 103(10):1457. PubMed ID: 4051846
    [No Abstract]   [Full Text] [Related]  

  • 2. Vitreous fluorophotometry in juvenile diabetics after oral fluorescein.
    Nuzzi G; Vanelli M; Venturini I; Bonacini M; Boselli E
    Arch Ophthalmol; 1986 Nov; 104(11):1630-1. PubMed ID: 3778277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the early stages of diabetic retinopathy by vitreous fluorophotometry.
    Cunha-Vaz JG; Gray JR; Zeimer RC; Mota MC; Ishimoto BM; Leite E
    Diabetes; 1985 Jan; 34(1):53-9. PubMed ID: 3964755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Posterior vitreous fluorophotometry. II. Comparison of diabetic patients and controls with the use of a new analysis procedure.
    Roy MS; Bungay PM; Bonner RF
    Arch Ophthalmol; 1989 Sep; 107(9):1328-33. PubMed ID: 2675803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of vitreous body integrity in retinitis pigmentosa by vitreous fluorophotometry.
    Ogura Y; Cunha-Vaz JG; Zeimer RC
    Arch Ophthalmol; 1987 Apr; 105(4):517-9. PubMed ID: 3566605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spectral shift of fluorescein and carboxyfluorescein in the anterior chamber of the rabbit eye following systemic administration.
    Neault TR; McLaren JW; Brubaker JH; Brubaker RF
    Curr Eye Res; 1986 May; 5(5):337-41. PubMed ID: 3720340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors affecting vitreous fluorescence.
    Mosier MA
    Graefes Arch Clin Exp Ophthalmol; 1985; 222(4-5):202-5. PubMed ID: 3979843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitreous fluorophotometry in vitreous degeneration.
    Plehwe WE; Kohner EM
    Arch Ophthalmol; 1987 Aug; 105(8):1019-20. PubMed ID: 3632404
    [No Abstract]   [Full Text] [Related]  

  • 9. Studies on the blood-retinal barrier after cryoretinopexy with vitreous fluorophotometry.
    Kato M; Ando F
    Nagoya J Med Sci; 1984 Mar; 46(1-4):79-86. PubMed ID: 6738681
    [No Abstract]   [Full Text] [Related]  

  • 10. Plasma fluorescein decay determination during fluorophotometry.
    Boot JP; Van Best JA; Tjin a Tsoi EW; Kappelhof JP; Oosterhuis JA
    Doc Ophthalmol; 1987 Apr; 65(4):403-22. PubMed ID: 3691293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of fluorescein in the vitreous.
    Palestine AG; Brubaker RF
    Invest Ophthalmol Vis Sci; 1981 Oct; 21(4):542-9. PubMed ID: 7287343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorescein and fluorescein glucuronide in vitreous: fluorescence and binding properties in vitro.
    Larsen M; Lund-Andersen H
    Acta Ophthalmol (Copenh); 1989 Apr; 67(2):137-40. PubMed ID: 2728864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitreous fluorophotometry in rats with streptozocin-induced diabetes.
    Vine AK; Kisly AM; Betz AL; Howatt WF
    Arch Ophthalmol; 1984 Jul; 102(7):1083-5. PubMed ID: 6743087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Posterior vitreous fluorophotometry. I. Description of a new analysis procedure and results in normal subjects.
    Bungay PM; Roy MS; Bonner RF
    Arch Ophthalmol; 1989 Sep; 107(9):1321-7. PubMed ID: 2783065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitreous fluorophotometry: identification of sources of variability.
    Prager TC; Wilson DJ; Avery GD; Merritt JH; Garcia CA; Hopen G; Anderson RE
    Invest Ophthalmol Vis Sci; 1981 Dec; 21(6):854-64. PubMed ID: 7309436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitreous fluorophotometry in patients with no or minimal diabetic retinopathy.
    Chahal P; Fallon TJ; Jennings SJ; Chowienczyk PJ; Kohner EM
    Diabetes Care; 1986; 9(2):134-9. PubMed ID: 3698779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitreous fluorophotometry in optic nerve disease.
    Braude LS; Cunha-Vaz JG; Frenkel M
    Br J Ophthalmol; 1982 Sep; 66(9):560-6. PubMed ID: 7104274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison between in vivo and in vitro fluorophotometry in the rabbit eye.
    van Best JA; van Delft JL; Oosterhuis JA
    Ophthalmic Res; 1983; 15(6):318-23. PubMed ID: 6669359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluorophotometry and the blood-ocular barrier in experimental systemic hypertension.
    Dutton JJ; Krupin T; Waltman SR; Koloms BA; Becker B
    Arch Ophthalmol; 1980 Apr; 98(4):731-3. PubMed ID: 7369911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of vitreous fluorophotometry to distinguish between diabetics with and without observable retinopathy: effect of vitreous abnormalities on the measurement.
    Prager TC; Chu HH; Garcia CA; Anderson RE; Field JB; Orzeck EA; Comstock JP
    Invest Ophthalmol Vis Sci; 1983 Jan; 24(1):57-65. PubMed ID: 6826315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.